AstraZeneca Sues 4 Drugmakers To Stop Generic Vimovo

Law360, New York (October 25, 2013, 5:32 PM ET) -- AstraZeneca AB sued four generic drugmakers this week in New Jersey federal court, accusing the pharmaceutical companies of infringing on its patent for the arthritis medication Vimovo. 

AstraZeneca on Thursday sued three pharmaceutical companies — Dr. Reddy’s Laboratories Inc., Lupin Ltd. and Actavis Inc. — and another, Mylan Pharmaceuticals, on Wednesday, to stop generic forms of Vimovo from entering the market after the companies filed multiple abbreviated new drug applications with the U.S. Food and Drug Administration.

The suits center on U.S. Patent No. 8,557,285, entitled “Pharmaceutical...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required